We continue to develop a comprehensive and relevant collection of models which are most representative of the wide range of CVMD related diseases.

Metabolic Disease

Metabolic Syndrome is a combination of medical disorders that, when occurring together, increase the risk of developing cardiovascular disease and diabetes. According to the World Health Organization at least 285 million people worldwide have diabetes today. This number is expected to reach 500 million by 2030. The pathophysiology of metabolic syndrome is extremely complex and remains only partially explained. With the rising clinical failure rate for drugs targeting diabetes and other metabolic syndromes, there is an urgent need to improve the preclinical candidates in models which closely represent human disease biology.

At Crown Bioscience, we provide models of biological pathways and drug mechanism of action in well-defined biological systems, which are translatable to human disease. Leveraging our expertise and our access to unique animal models, we are redefining translational research in this important disease area, providing a validated Translational Platform for our clients.

Target discovery & Validation

Despite the pandemic proportion of metabolic diseases, the number of drugs and drug targets for these diseases remains limited. A key challenge has been the difficulty to access affected relevant tissues.

The ability to collect tissues at specific stages of the disease allows us to accurately determine and understand its onset, progression, and manifestation. The screening of the dynamic changes in the tissue (i.e. gene expression) provides important clues for the discovery and validation of new targets.

The Cardiovascular and Metabolic Disease Research (CVMD) program’s focus is to provide a world class platform for drug discovery and development, including diseased animal models and translational research labs. We provide a comprehensive suite of models and services, and a number of unique models and capabilities:

  • the world’s largest collection of naturally occurring diabetic cynomolgus and rhesus monkeys.
  • the largest population of primates with dysmetabolic syndrome in the world.
  • an animal tissue bank.
  • traditional genetically-modified, chemically-induced diabetic and novel rodent models for early drug discovery including novel diabetic rat (ZDSD) and mouse (FATZO) models which are obese, hyperglycemic but without mutations in the Leptin pathway, as well as the Polycystic Kidney Disease (PKD) mouse model from PreClinOmics (a CrownBio Company).

Contact us to find out more about our unique models and capabilities and how we can help advance your research programs.